Hypnion, Inc.

Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275

Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275

January 5, 2007

Primary and Secondary Efficacy Endpoints
Achieved Statistical Significance

Study Validated Drug's Unique H1 / 5HT2a
Mechanisms of Action

Drug Was Very Well Tolerated

Hypnion, Inc.

Lilly Announces Acquisition of Hypnion

Lilly Announces Acquisition of Hypnion

March 5, 2007

Deal Will Bolster Lilly's Sleep Disorder Research With Promising Insomnia Compound

Hypnion, Inc.

Lilly Announces Completion of Hypnion Acquisition

Lilly Announces Completion of Hypnion Acquisition

April 3, 2007

INDIANAPOLIS, April 3, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has completed its acquisition of Hypnion, Inc., a privately held neuroscience drug discovery company focused on sleep disorder research.

AVEO Pharmaceuticals, Inc.

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin

January 4, 2007

AVEO adds Phase II-ready VEGF receptor inhibitor to growing product portfolio

BG Medicine, Inc.

Flagship Portfolio Company BG Medicine Announces Major Collaborative Research Effort to Prevent Heart Attack & Stroke

Flagship Portfolio Company BG Medicine Announces Major Collaborative Research Effort to Prevent Heart Attack & Stroke

January 30, 2007

BG Medicine today announced the initiation of a multi-year research project, funded by Merck, AstraZeneca and Philips Medical, aimed at better understanding high risk plaque in heart attack and stroke.  The project will harness BGM’s systems biology measurement approaches along with state-of-the art medical imaging techniques to identify new approaches for the detection and treatment of vulnerable patients.

Epitome Biosystems

Epitome Biosystems Completes Development of Multiplex Assays for EMD Biosciences Inc.

Epitome Biosystems Completes Development of Multiplex Assays for EMD Biosciences Inc.

January 31, 2007

Waltham, MA, and Madison, WI, January 31, 2007 – Epitome Biosystems and EMD Biosciences Inc. announced today the successful completion of a collaboration to develop multiplex assays to measure phosphorylation of cell signaling proteins using Epitome’s EpiTag™ technology. Epitome developed custom antibody and peptide reagents to enable quantitative protein measurements of selected targets for EMD Biosciences. This completes the first commercial partnership for Epitome.

Adnexus Therapeutics

Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans

Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans

February 2, 2007

Angiogenesis Inhibitor, CT-322, Shows Biological Activity at First Dose Level Tested

Helicos BioSciences Corporation

Helicos BioSciences Announces a Novel Homopolymer Solution for True Single Molecule Sequencing (tSMS™)

Helicos BioSciences Announces a Novel Homopolymer Solution for True Single Molecule Sequencing (tSMS™)

February 9, 2007

The company’s researchers have developed proprietary nucleotide-polymerase formulations that enable sequencing through homopolymers.

VisEn Medical, Inc.

Industry Veteran Erik Wallden Joins VisEn Medical Board of Directors

Industry Veteran Erik Wallden Joins VisEn Medical Board of Directors

February 8, 2007

Woburn, MA (February 8, 2007) -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, today announced that Erik Wallden has joined the company’s Board of Directors. Previously, Mr. Wallden served as the President and CEO of Biacore International AB, which was sold after a successful turnaround to GE Healthcare in September, 2006.

Epitome Biosystems

Epitome Biosystems Expands Senior Management Team

Epitome Biosystems Expands Senior Management Team

February 13, 2007

Jeffrey Radding Draws on Pharmaceutical Experience to Lead Research and Development

Waltham, MA, February 13, 2007 – Epitome Biosystems, a biotechnology company focused on innovative protein measurement systems, announced today the appointment of Jeffrey Radding, Ph.D., as Vice President, Research & Development. Dr. Radding joins the Company from Eli Lilly, where he led the Platform Biology Group in evaluating and implementing cell signaling approaches for drug discovery across multiple therapeutic areas.